Akari Therapeutics Appoints Samir R. Patel As Interim CEO; Plans For Prioritization Of Peak Bio's ADC Cancer Therapeutic Platform Technology And Akari's PAS-Nomacopan For Geographic Atrophy
Akari Therapeutics Appoints Samir R. Patel As Interim CEO; Plans For Prioritization Of Peak Bio's ADC Cancer Therapeutic Platform Technology And Akari's PAS-Nomacopan For Geographic Atrophy
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders
Samir R. Patel萬.D. 被任命爲臨時CEO；臨時CEO的僱傭合同表明與股東的利益一致。
Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy
制定Peak Bio的ADC癌症治療平台技術和Akari的PAS-nomacopan在地理萎縮方面的優先安排計劃。
Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes
現有投資者通過發行價值100萬美元的無擔保可轉換票據支持公司。
Secured $7.6 Million in Upsized Financing Round
通過增加融資輪次獲得760萬美元的擔保資金。
Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
在處理地理萎縮症方面，接收到美國FDA對PAS-nomacopan的積極和建設性的臨床前反饋。
BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the second quarter ended June 30, 2024 as well as recent company highlights.
波士頓和倫敦，2024年8月19日（全球新聞通訊社）-- Akari Therapeutics, Plc（納斯達克股票代碼：AKTX）是一家創新的生物技術公司，致力於開發先進的自身免疫和炎症性疾病治療方案，並報告了截至2024年6月30日的第二季度財務業績以及公司最近的亮點。
譯文內容由第三人軟體翻譯。
